PL3539551T3 - Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli - Google Patents

Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli

Info

Publication number
PL3539551T3
PL3539551T3 PL19158126T PL19158126T PL3539551T3 PL 3539551 T3 PL3539551 T3 PL 3539551T3 PL 19158126 T PL19158126 T PL 19158126T PL 19158126 T PL19158126 T PL 19158126T PL 3539551 T3 PL3539551 T3 PL 3539551T3
Authority
PL
Poland
Prior art keywords
related disorders
receptor related
heterozygous carriers
treating melanocortin
melanocortin
Prior art date
Application number
PL19158126T
Other languages
English (en)
Inventor
Louis A. Tartaglia
Bart Henderson
Original Assignee
Rhythm Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals, Inc. filed Critical Rhythm Pharmaceuticals, Inc.
Publication of PL3539551T3 publication Critical patent/PL3539551T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19158126T 2011-12-29 2012-12-28 Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli PL3539551T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161581391P 2011-12-29 2011-12-29
PCT/US2012/072026 WO2013102047A1 (en) 2011-12-29 2012-12-28 Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
EP12863862.4A EP2797615B1 (en) 2011-12-29 2012-12-28 Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
EP19158126.3A EP3539551B1 (en) 2011-12-29 2012-12-28 Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

Publications (1)

Publication Number Publication Date
PL3539551T3 true PL3539551T3 (pl) 2022-02-21

Family

ID=48698641

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19158126T PL3539551T3 (pl) 2011-12-29 2012-12-28 Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli

Country Status (15)

Country Link
US (5) US9845339B2 (pl)
EP (3) EP2797615B1 (pl)
CA (2) CA3301962A1 (pl)
CY (1) CY1124816T1 (pl)
DK (2) DK3539551T3 (pl)
ES (2) ES2897559T3 (pl)
HR (1) HRP20211950T1 (pl)
HU (1) HUE056948T2 (pl)
LT (1) LT3539551T (pl)
PL (1) PL3539551T3 (pl)
PT (2) PT3539551T (pl)
RS (1) RS62701B1 (pl)
SI (1) SI3539551T1 (pl)
SM (1) SMT202100734T1 (pl)
WO (1) WO2013102047A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3301962A1 (en) 2011-12-29 2026-03-02 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
PT3356386T (pt) 2015-09-30 2024-05-17 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados à via do receptor da melanocortina-4
AR113885A1 (es) 2017-11-15 2020-06-24 Rhythm Pharmaceuticals Inc Formulaciones de péptidos de liberación sostenida
AU2019249255A1 (en) * 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN120699097A (zh) * 2024-09-03 2025-09-26 万邦德制药集团有限公司 一种二硫环肽化合物及其制备方法和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
AU2004251616A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
KR100997177B1 (ko) 2005-07-08 2010-11-29 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US8058240B2 (en) * 2006-04-18 2011-11-15 University Of Florida Research Foundation, Inc. Biological active ligands of melanocortin receptors
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2104684A1 (en) 2007-01-18 2009-09-30 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
EP2148692B1 (en) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
TR201815292T4 (tr) 2007-11-05 2018-11-21 Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi.
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
CA2731897C (en) 2008-08-06 2013-07-02 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
EP2320738A4 (en) 2008-08-29 2011-08-24 Transtech Pharma Inc SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP2012509862A (ja) 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
KR20120059520A (ko) * 2009-08-05 2012-06-08 입센 파마 에스.에이.에스 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도
ES2624451T3 (es) 2009-08-31 2017-07-14 Tensive Controls, Inc. Ligandos de melanocortina estabilizados
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
JP2013510881A (ja) 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
CA3301962A1 (en) 2011-12-29 2026-03-02 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US10196425B2 (en) 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
PT2970389T (pt) 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas
PT3356386T (pt) 2015-09-30 2024-05-17 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados à via do receptor da melanocortina-4
AR113885A1 (es) 2017-11-15 2020-06-24 Rhythm Pharmaceuticals Inc Formulaciones de péptidos de liberación sostenida

Also Published As

Publication number Publication date
US20180194803A1 (en) 2018-07-12
HUE056948T2 (hu) 2022-04-28
EP3988108A1 (en) 2022-04-27
WO2013102047A1 (en) 2013-07-04
US9845339B2 (en) 2017-12-19
CA2862444A1 (en) 2013-07-04
PT2797615T (pt) 2019-07-11
ES2732077T3 (es) 2019-11-20
LT3539551T (lt) 2022-01-10
RS62701B1 (sr) 2022-01-31
HRP20211950T1 (hr) 2022-03-18
CY1124816T1 (el) 2022-11-25
EP3539551B1 (en) 2021-10-06
EP3539551A1 (en) 2019-09-18
EP2797615A4 (en) 2016-05-18
US11702448B2 (en) 2023-07-18
EP2797615B1 (en) 2019-04-03
WO2013102047A8 (en) 2014-02-27
DK2797615T3 (da) 2019-07-01
SMT202100734T1 (it) 2022-03-21
SI3539551T1 (sl) 2022-02-28
US20210061852A1 (en) 2021-03-04
US20140329743A1 (en) 2014-11-06
PT3539551T (pt) 2021-11-04
US10167312B2 (en) 2019-01-01
US10954268B2 (en) 2021-03-23
ES2897559T3 (es) 2022-03-01
US20240190914A1 (en) 2024-06-13
EP2797615A1 (en) 2014-11-05
US20200017546A1 (en) 2020-01-16
DK3539551T3 (da) 2021-11-01
CA3301962A1 (en) 2026-03-02

Similar Documents

Publication Publication Date Title
IL281178B (en) Methods of treating or preventing cholesterol related disorders
PL2726099T3 (pl) Sposób leczenia zaburzeń metabolicznych
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
EP4026901C0 (en) Method for screening alpha-amylases
DK3366775T3 (da) Modificerede rnai-midler
IL232222A0 (en) Methods for treating progressive multiple sclerosis
EP2780299A4 (en) FUNCTION MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
EP2692387A4 (en) CATHETER ARRANGEMENT
DK2511521T4 (da) Pitch-leje
ZA201401438B (en) Methods for treating cardiovascular disorders
BR112014009795A2 (pt) método
BR112014007266A2 (pt) método para fornecer anúncio personalizado
BR112014007958A2 (pt) método
BR112014001765A2 (pt) método
BR112014001237A2 (pt) método
HUE044650T2 (hu) Eljárás EFP kezelésére vagy csökkentésére
BR112014011115A2 (pt) métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
HUE056948T2 (hu) Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban
EP2712063A4 (en) PRESSURE FORMING STRUCTURE
IT1406864B1 (it) Composizione per il trattamento dell'acne
FR2982241B1 (fr) Harpon d'ancrage et procede d'ancrage associe
FR2974628B1 (fr) Microdebitmetre et son procede de realisation
EP2697339A4 (en) INTEGRATED HYDROGEN TREATMENT, HYDROGEN PARTICULARIZATION AND HYDROPROTECTION PROCESS
FR2975585B1 (fr) Implant textile et procede pour sa realisation
DE112012000253A5 (de) Vorrichtung zum bördeln von rohrenden